keyword
MENU ▼
Read by QxMD icon Read
search

alcoholic fatty liver

keyword
https://www.readbyqxmd.com/read/28430653/preventive-effects-of-the-sodium-glucose-cotransporter-2-inhibitor-tofogliflozin-on-diethylnitrosamine-induced-liver-tumorigenesis-in-obese-and-diabetic-mice
#1
Koki Obara, Yohei Shirakami, Akinori Maruta, Takayasu Ideta, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Takuji Tanaka, Mitsuru Seishima, Masahito Shimizu
Sodium glucose cotransporter 2 inhibitors are expected to ameliorate the abnormalities associated with metabolic syndrome including non-alcoholic fatty liver disease. In this study, we investigated the effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on the development of non-alcoholic fatty liver disease-related liver tumorigenesis in C57BL/KsJ-+Leprdb/+Leprdb obese and diabetic mice. The direct effects of tofogliflozin on human liver cancer cell proliferation were also evaluated. Mice were administered diethylnitrosamine-containing water for 2 weeks and were treated with tofogliflozin throughout the experiment...
April 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28429814/sulfated-polysaccharides-from-enteromorpha-prolifera-suppress-srebp-2-and-hmg-coa-reductase-expression-and-attenuate-non-alcoholic-fatty-liver-disease-induced-by-a-high-fat-diet
#2
Rendong Ren, Junjie Gong, Yanyan Zhao, Xinyun Zhuang, Yin Ye, Wenting Lin
Non-alcoholic fatty liver disease (NAFLD) is caused by fat accumulation and is associated with abnormal cholesterol metabolism. Previous work indicates that polysaccharides from alga Enteromorpha prolifera improve glucose metabolism and lower cholesterol in diabetic rats. Thus, we studied the possible protective effects of E. prolifera polysaccharides (EP) in the development of NAFLD and underlying mechanisms. EP (200 mg kg(-1)) significantly reduced the liver weight and significantly lowered hepatic HMG-CoA reductase (HMGCR) mRNA protein expression...
April 21, 2017: Food & Function
https://www.readbyqxmd.com/read/28429344/up-regulation-of-microrna-367-promotes-liver-steatosis-through-repressing-tbl1-in-obese-mice
#3
D-D Li, Y Liu, L Xue, D-Y Su, W-Y Pang
OBJECTIVE: Increasing evidence has demonstrated that microRNAs (miRNAs) play a critical role in the progression of metabolic disorders, including obesity-induced non-alcoholic fatty liver disease (NAFLD). In the present study, the expression and function of miR-367 were investigated. MATERIALS AND METHODS: C57BL/6 male mice aged 8 weeks were fed with a normal diet (ND) or high-fat-diet (HFD). The expression levels of miR-367 were analyzed in livers from two groups of mice by quantitative real-time PCR...
April 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28429199/gastric-bypass-and-influence-on-improvement-of-nafld
#4
REVIEW
Vamsi Alli, Ann M Rogers
PURPOSE OF REVIEW: Obesity is recognized as a chronic and recurring disease, often accompanied by other weight-related comorbid conditions such as obstructive sleep apnea, hypertension, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). This chapter will seek to focus on the effect of weight loss surgery (WLS), in particular Roux-en-Y gastric bypass (RYGB), on NAFLD. RECENT FINDINGS: Among several modalities available to treat NAFLD, the one most likely to achieve rapid, significant, and sustained improvement of liver disease is WLS...
June 2017: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/28428116/cycloastragenol-improves-hepatic-steatosis-by-activating-farnesoid-x-receptor-signalling
#5
Ming Gu, Shiying Zhang, Yuanyuan Zhao, Jinwen Huang, Yahui Wang, Yin Li, Shengjie Fan, Li Yang, Guang Ji, Qingchun Tong, Cheng Huang
Non-alcoholic fatty liver disease (NAFLD) has become a global health problem. However, there is no approved therapy for NAFLD. Farnesoid X receptor (FXR) is a potential drug target for treatment of NAFLD. In an attempt to screen FXR agonists, we found that cycloastragenol (CAG), a natural occurring compound in Astragali Radix, stimulated FXR transcription activity. In animal studies, we demonstrated that CAG treatment resulted in obvious reduction of high-fat diet induced lipid accumulation in liver accompanied by lowered blood glucose, serum triglyceride levels and hepatic bile acid pool size...
April 17, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28426902/hepatic-steatosis-after-pediatric-liver-transplant
#6
Emily R Perito, Tabitha Vase, Rageshree Ramachandran, Andrew Phelps, Kuang-Yu Jen, Robert H Lustig, Vickie A Feldstein, Philip Rosenthal
RATIONALE: Hepatic steatosis develops after liver transplant in 30% of adults, and non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in non-transplanted children. However, post-transplant steatosis has been minimally studied in pediatric liver transplant recipients. We explored the prevalence, persistence, and association with chronic liver damage of hepatic steatosis in these children. RESULTS: In this single-center study of pediatric patients transplanted 1988-2015 (n=318), 31% of those with any post-transplant biopsy (n=271) had ≥1 biopsy with steatosis...
April 20, 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28426878/microbiota-nash-hcc-and-the-potential-role-of-probiotics
#7
Giovanni Brandi, Stefania De Lorenzo, Marco Candela, Maria Abbondanza Pantaleo, Stefano Bellentani, Francesco Tovoli, Gioconda Saccoccio, Guido Biasco
Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. Clearly identifiable risk factors are lacking in up to 30% of HCC patients and most of these cases are attributed to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Beyond the known risk factors for NAFLD, the intestinal microbiota, in particular dysbiosis (defined as any change in the composition of the microbiota commonly found in healthy conditions) is emerging as a new factor promoting the development of chronic liver diseases and HCC...
March 1, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/28426815/using-controlled-attenuation-parameter-combined-with-ultrasound-to-survey-non-alcoholic-fatty-liver-disease-in-hemodialysis-patients-a-prospective-cohort-study
#8
Yi-Hao Yen, Jin-Bor Chen, Ben-Chung Cheng, Jung-Fu Chen, Kuo-Chin Chang, Po-Lin Tseng, Cheng-Kun Wu, Ming-Chao Tsai, Ming-Tsung Lin, Tsung-Hui Hu
BACKGROUND AND AIMS: Controlled attenuation parameter (CAP) is a non-invasive method for measuring hepatic steatosis (HS). Non-alcoholic fatty liver disease (NAFLD) is closely related to cardiovascular diseases (CVDs). CVDs are the leading cause of morbidity and mortality in hemodialysis patients. The aim of this study was to investigate the prevalence of NAFLD in hemodialysis patients. METHOD: We prospectively enrolled patients undergoing chronic hemodialysis, as well as patients with normal renal function who served as controls...
2017: PloS One
https://www.readbyqxmd.com/read/28426073/ameliorative-effects-of-pepsin-digested-chicken-liver-hydrolysates-on-development-of-alcoholic-fatty-livers-in-mice
#9
Yi-Ling Lin, Szu-Yun Tai, Jr-Wei Chen, Chung-Hsi Chou, Shih-Guei Fu, Yi-Chen Chen
With developments in economics and increasing work loads, alcohol abuse becomes more and more severe, leading to occurrences of alcoholic liver disease (ALD). Pepsin-digested chicken liver hydrolysates (CLHs) contain high amounts of glutamic acid, leucine, lysine, and alanine while the contents of taurine, anserine, and carnosine are also elevated after pepsin hydrolyzation. The objectives of this study were to evaluate the protective effects of CLHs against chronic alcohol consumption. The results indicated that the enlarged (p < 0...
April 20, 2017: Food & Function
https://www.readbyqxmd.com/read/28424943/intestinal-alkaline-phosphatase-attenuates-alcohol-induced-hepatosteatosis-in-mice
#10
Sulaiman R Hamarneh, Byeong-Moo Kim, Kanakaraju Kaliannan, Sara A Morrison, Tyler J Tantillo, Qingsong Tao, Mussa M Rafat Mohamed, Juan M Ramirez, Aaron Karas, Wei Liu, Dong Hu, Abeba Teshager, Sarah Shireen Gul, Konstantinos P Economopoulos, Atul K Bhan, Madhu S Malo, Michael Y Choi, Richard A Hodin
BACKGROUND AND AIMS: Bacterially derived factors from the gut play a major role in the activation of inflammatory pathways in the liver and in the pathogenesis of alcoholic liver disease. The intestinal brush-border enzyme intestinal alkaline phosphatase (IAP) detoxifies a variety of bacterial pro-inflammatory factors and also functions to preserve gut barrier function. The aim of this study was to investigate whether oral IAP supplementation could protect against alcohol-induced liver disease...
April 19, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28424263/the-kielin-chordin-like-protein-kcp-attenuates-high-fat-diet-induced-obesity-and-metabolic-syndrome-in-mice
#11
Abdul Soofi, Katherine I Wolf, Margo P Emont, Nathan Qi, Gabriel Martinez-Santibanez, Edward Grimley, Wesam Ostwani, Gregory R Dressler
Obesity and its associated complications, such as insulin resistance and non-alcoholic fatty liver disease, are reaching epidemic proportions. In mice, the TGF-beta superfamily is implicated in the regulation of white and brown adipose tissue differentiation. The Kielin/chordin-like Protein (KCP) is a secreted regulator of the TGF-beta superfamily pathways that can inhibit both TGF-beta and activin signals while enhancing bone morphogenetic protein (BMP) signaling. However, KCP's effects on metabolism and obesity have not been studied in animal models...
April 19, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28422172/transient-elastography-as-a-screening-tool-for-liver-fibrosis-in-a-large-hemodialysis-population
#12
Ben-Chung Cheng, Yi-Hao Yen, Jung-Fu Chen, Cheng-Kun Wu, Kuo-Chin Chang, Po-Lin Tseng, Ming-Chao Tsai, Ming-Tsung Lin, Jung-Ting Lin, Jin-Bor Chen, Tsung-Hui Hu
Metabolic syndrome, an etiological factor in non-alcoholic fatty liver disease (NAFLD), is often present in hemodialysis patients. Little is known about the prevalence of, and factors associated with, liver fibrosis in hemodialysis populations. We used transient elastography (TE) to investigate these phenomena. 659 patients treated with chronic hemodialysis were enrolled. We excluded those with excess alcohol intake, liver stiffness measurement (LSM) failure, or unreliable LSM values. LSM ≥8.0 kPa was used as a cutoff suggesting clinically relevant fibrosis...
April 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28420094/nonalcoholic-fatty-liver-disease-and-insulin-resistance-new-insights-and-potential-new-treatments
#13
REVIEW
Hironori Kitade, Guanliang Chen, Yinhua Ni, Tsuguhito Ota
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders worldwide. It is associated with clinical states such as obesity, insulin resistance, and type 2 diabetes, and covers a wide range of liver changes, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma. Metabolic disorders, such as lipid accumulation, insulin resistance, and inflammation, have been implicated in the pathogenesis of NAFLD, but the underlying mechanisms, including those that drive disease progression, are not fully understood...
April 14, 2017: Nutrients
https://www.readbyqxmd.com/read/28419855/a-randomized-trial-of-silymarin-for-the-treatment-of-non-alcoholic-steatohepatitis
#14
Wah-Kheong Chan, Nik Raihan Nik Mustapha, Sanjiv Mahadeva
BACKGROUND & AIMS: Silymarin is a complex mixture of 6 major flavonolignans and other minor polyphenolic compounds derived from the milk thistle plant Silybum marianum; it has shown anti-oxidant, anti-inflammatory and anti-fibrotic effects, and may be useful in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to study the efficacy of silymarin in patients with non-alcoholic steatohepatitis (NASH)-the more severe form of NAFLD. METHODS: We performed a randomized, double-blind, placebo-controlled trial of consecutive adults with biopsy-proven NASH and a NAFLD activity score (NAS) of 4 or more at a tertiary care hospital in Kuala Lumpur, Malaysia, from November 2012 through August 2014...
April 15, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28419124/a-randomised-controlled-trial-of-losartan-as-an-anti-fibrotic-agent-in-non-alcoholic-steatohepatitis
#15
Stuart McPherson, Nina Wilkinson, Dina Tiniakos, Jennifer Wilkinson, Alastair D Burt, Elaine McColl, Deborah D Stocken, Nick Steen, Jane Barnes, Nicola Goudie, Stephen Stewart, Yvonne Bury, Derek Mann, Quentin M Anstee, Christopher P Day
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis in patients with non-alcoholic steatohepatitis (NASH). METHODS: Double-blind randomised-controlled trial of Losartan 50 mg once a day versus placebo for 96 weeks in patients with histological evidence of NASH...
2017: PloS One
https://www.readbyqxmd.com/read/28419000/exercise-induced-autophagy-in-fatty-liver-disease
#16
Sung Kook Chun, Sooyeon Lee, Ming-Jim Yang, Christiaan Leeuwenburgh, Jae-Sung Kim
Hepatic steatosis prevails each year. Autophagy is integral in mitochondrial quality control and lipid homeostasis in the liver. No pharmacological strategies are currently available to reduce hepatic steatosis, but exercise has been known to improve clinical outcomes of chronic liver disease, particularly non-alcoholic fatty liver disease (NAFLD). Recent studies suggest that exercise may improve NAFLD through enhancing autophagy.
April 17, 2017: Exercise and Sport Sciences Reviews
https://www.readbyqxmd.com/read/28417532/non-alcoholic-fatty-liver-disease-nafld-prevalence-and-its-metabolic-associations-in-patients-with-type-1-diabetes-and-type-2-diabetes
#17
Kenneth Cusi, Arun J Sanyal, Shuyu Zhang, Mark L Hartman, Juliana M Bue-Valleskey, Byron J Hoogwerf, Axel Haupt
We investigated non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes (T1D), and in insulin-naïve and insulin-treated patients with type 2 diabetes (T2D). Baseline data from patients who had liver fat content (LFC) evaluated by magnetic resonance imaging in 4 phase 3 studies of basal insulin peglispro (BIL) were analyzed. Associations of NAFLD with clinical characteristics, glycemic control and diabetes therapy were evaluated. The prevalence of NAFLD (defined as LFC ≥6%) was low in T1D (8...
April 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28416740/multi-targeting-therapeutic-mechanisms-of-the-chinese-herbal-medicine-qhd-in-the-treatment-of-non-alcoholic-fatty-liver-disease
#18
Qin Feng, Wensheng Liu, Susan S Baker, Hongshan Li, Cheng Chen, Qian Liu, Shijie Tang, Lingyu Guan, Maria Tsompana, Rafal Kozielski, Robert D Baker, Jinghua Peng, Ping Liu, Ruixin Zhu, Yiyang Hu, Lixin Zhu
Beneficial effects of the Chinese herbal medicine Qushi Huayu Decoction (QHD) were observed with non-alcoholic fatty liver disease (NAFLD) patients and animal models. The impact of QHD or its active components (geniposide and chlorogenic acid, GC) on NAFLD liver transcriptome and gut microbiota was examined with NAFLD rats. Increased expression for genes required for glutathione production and decreased expression for genes required for lipid synthesis was observed in NAFLD livers treated with QHD and GC. GC treatment decreased serum LPS, which could be explained by reduced mucosal damage in the colon of GC-treated rats...
February 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415736/the-gamma-glutamyl-transpeptidase-to-platelet-ratio-for-non-invasive-assessment-of-liver-fibrosis-in-patients-with-chronic-hepatitis-b-and-non-alcoholic-fatty-liver-disease
#19
Qiang Li, Chuan Lu, Weixia Li, Yuxian Huang, Liang Chen
BACKGROUND/AIM: The gamma-glutamyl transpeptidase-to-platelet ratio (GPR) is a novel serum model, which was reported more accurate than aspartate transaminase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) for diagnosing significant fibrosis and cirrhosis in HBV mono-infection in West Africa. We aimed to evaluate the diagnostic performance of GPR for liver fibrosis in patients with chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD)...
March 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414763/enhanced-offspring-predisposition-to-steatohepatitis-with-maternal-high-fat-diet-is-associated-with-epigenetic-and-microbiome-alterations
#20
Umesh D Wankhade, Ying Zhong, Ping Kang, Maria Alfaro, Sree V Chintapalli, Keshari M Thakali, Kartik Shankar
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is an important co-morbidity associated with obesity and a precursor to steatohepatitis. However, the contributions of gestational and early life influences on development of NAFLD and NASH remain poorly appreciated. METHODS: Two independent studies were performed to examine whether maternal over-nutrition via exposure to high fat diet (HFD) leads to exacerbated hepatic responses to post-natal HFD and methionine choline deficient (MCD) diets in the offspring...
2017: PloS One
keyword
keyword
29198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"